CF
EWTX icon

Corebridge Financial’s Edgewise Therapeutics EWTX Stock Holding History

Corebridge Financial’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,049
Closed -$793K – 929
2025
Q1 		$793K Sell
36,049
-41
-0.1% -$1.08K ﹤0.01% 1369
2024
Q4 		$964K Sell
36,090
-2,724
-7% -$86.7K 0.01% 1342
2024
Q3 		$1.04M Sell
38,814
-240
-0.6% -$4.77K 0.01% 1344
2024
Q2 		$703K Buy
+39,054
New +$681K ﹤0.01% 1518

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Corebridge Financial's EWTX Position: Q2 2025 in Review

Corebridge Financial sold out of Edgewise Therapeutics (EWTX) in Q2 2025, closing a stake of 36,049 shares — an estimated $793K sold.

Corebridge Financial first reported a position in EWTX in Q2 2024 and held it in 4 quarters. The position peaked at $1.04M in Q3 2024. 178 funds tracked by Wall St. Rank hold EWTX as of Q2 2025.

  • Corebridge Financial reported no remaining Edgewise Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 36,049 Edgewise Therapeutics shares in Q2 2025, an estimated $793K.
  • Corebridge Financial first reported a position in Edgewise Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Edgewise Therapeutics position peaked at $1.04M in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.